Description
The global tumor ablation market is projected to reach USD 4.15 Billion by 2032, from USD 1.67 Billion in 2024, reflecting sustained momentum in minimally invasive oncology interventions. Tumor ablation, an image-guided, minimally invasive technique, leverages energy modalities such as radiofrequency, microwave, cryotherapy, and laser to selectively destroy cancerous tissue while preserving surrounding healthy structures. Its high precision and lower procedural burden have positioned it as a preferred option for treating small tumors, particularly in the liver, lungs, and kidneys.
The growing adoption of precision oncology and personalized treatment pathways continues to accelerate demand for these modalities, as clinicians increasingly seek targeted solutions that minimize adverse effects and improve patient outcomes. Additionally, the technological advancements to enhance accuracy, portability, and cost-effectiveness are likely to encourage market players to constantly improve and launch advanced tumor ablation devices. For instance, in December 2024, AngioDynamics, Inc. received U.S. Food and Drug Administration (FDA) 510(k) clearance for the NanoKnife System for prostate tissue ablation, underscoring the expanding clinical utility and regulatory momentum within the sector.
Recent Developments
• In February 2025, Boston Scientific Corporation received CE Mark approval for the FARAWAVE NAV Ablation Catheter, a navigation technology designed for the treatment of paroxysmal atrial fibrillation (PFA), and the new FARAVIEW Module.
• In May 2025, Stryker announced that its OptaBlate basivertebral nerve ablation system (OptaBlate BVN) received 510(k) clearance from the U.S. Food and Drug Administration. OptaBlate BVN is used in a targeted minimally invasive procedure providing long-lasting vertebrogenic pain relief.
• In March 2024, Medtronic plc received U.S. Food and Drug Administration (FDA) 510(k) clearance for its OsteoCool 2.0 bone tumor ablation system for the treatment of painful bone metastases and benign bone tumors such as osteoid osteoma.
Key Highlights of the Report
• In terms of technology, the radiofrequency ablation segment accounted for the largest share of market revenue, driven by its demonstrated specificity and procedural efficiency in ablating solid tumors, particularly in the liver, lung, and kidney.
• The microwave ablation segment is expected to record the fastest growth over the forecast period. Unlike radiofrequency systems that rely on electrical current, microwave ablation devices generate an electromagnetic field, enabling more efficient energy delivery. This capability enhances performance in tissues with low electrical conductivity, such as bone and lung, thereby broadening the clinical applicability of microwave-based interventions.
• Cryoablation which involves freezing the tumor cells is gaining traction, particularly for cancers involving the liver, kidneys, and prostate, where its precision and favorable safety profile are driving increased clinical adoption.
• High-intensity focused ultrasound (HIFU) accounted for a low double-digit share of the global tumor ablation market in 2024. As an emerging modality, HIFU leverages concentrated ultrasound waves to noninvasively ablate targeted tissue, and its growing clinical validation continues to support gradual adoption across oncology applications.
• Based on treatment mode, the percutaneous ablation segment led the global tumor ablation market, supported by its advantages of faster recovery, minimal scarring, and an overall improved safety profile compared with more invasive alternatives.
• Surgical ablation continues to serve as a conventional yet highly effective option for managing a broad range of tumor types.
• The laparoscopic ablation segment is projected to experience the fastest growth over the forecast period, supported by its ability to provide direct visualization of tumors and deliver precise treatment in anatomically complex cases.
• By application, the liver cancer segment held the largest share of the global tumor ablation market, driven by the high global incidence of liver cancer and the growing preference for minimally invasive therapeutic alternatives.
• Kidney cancer accounted for a significant share of the global tumor ablation market in 2024, supported by the rising global prevalence of renal malignancies and increasing adoption of minimally invasive ablation techniques for managing renal tumors.
• In terms of end-user, hospitals represent the largest segment of the tumor ablation market, driven by their comprehensive healthcare services and broad access to diverse patient populations.
• Oncology centers accounted for a significant share of the global tumor ablation market in 2024. These specialized facilities focus exclusively on cancer care, offering comprehensive services supported by advanced technologies and highly skilled specialists, making them a preferred choice for patients seeking specialized treatment.
• By region, North America leads the global tumor ablation market, supported by high healthcare expenditure, advanced medical technologies, and a well-established healthcare infrastructure.
• Europe represents the second largest market for tumor ablation, driven by an aging population, increasing cancer prevalence, and supportive government initiatives promoting the adoption of ablation therapies.
• The Asia Pacific region is projected to register the fastest growth over the forecast period, driven by significant untapped opportunities in emerging economies, including China and India.
• South America and the Middle East & Africa are emerging as competitive regions, each striving to capture a larger share of the global tumor ablation market.
Apelo Consulting report titled “Global Tumor Ablation Market (By Technology, Treatment Mode, Application, End User, Region), Company Profiles, Product Portfolio, Recent Developments, Key Trends and Market Dynamics – Global Forecast to 2032” provides a complete assessment of the fast–evolving, high–growth Global Tumor Ablation landscape.
This 199 Pages report with 110 Figures and 10 Tables has been analyzed from 9 pointers:
1. Global Tumor Ablation Market and Forecast (2018 – 2032)
2. Global Tumor Ablation Market Share and Forecast (2018 – 2032)
3. By Technology – Global Tumor Ablation Market and Forecast (2018 – 2032)
4. By Treatment Mode – Global Tumor Ablation Market and Forecast (2018 – 2032)
5. By Application – Global Tumor Ablation Market and Forecast (2018 – 2032)
6. By End-User – Global Tumor Ablation Market and Forecast (2018 – 2032)
7. By Region – Tumor Ablation Market and Forecast (2018 – 2032)
8. Global Tumor Ablation Market – Company Profiles
9. Global Tumor Ablation Market Dynamics – Key Trends, Growth Drivers & Challenges
Global Tumor Ablation Market and Forecast – By Technology
• Radiofrequency Ablation
• Microwave Ablation
• Cryoablation
• HIFU
• Irreversible Electroporation Ablation
• Others
Global Tumor Ablation Market and Forecast – By Treatment Mode
• Percutaneous Ablation
• Surgical Ablation
• Laparoscopic Ablation
Global Tumor Ablation Market and Forecast – By Application
• Liver Cancer
• Kidney Cancer
• Lung Cancer
• Breast Cancer
• Prostate Cancer
• Bone Cancer
• Other Cancers
Global Tumor Ablation Market and Forecast – By End-User
• Hospitals
• Oncology Centers
• Others
Global Tumor Ablation Market and Forecast – By Region
1. North America
• United States
• Canada
• Mexico
2. Europe
• Germany
• United Kingdom
• France
• Italy
• Spain
• Denmark
• Norway
• Sweden
• Belgium
• Netherlands
• Switzerland
• Rest of Europe
3. Asia Pacific
• Japan
• China
• India
• South Korea
• Thailand
• Australia
• Rest of Asia Pacific
4. South America
• Brazil
• Argentina
• Rest of South America
5. Middle East & Africa
• Saudi Arabia
• UAE
• Kuwait
• South Africa
• Rest of Middle East and Africa
Global Tumor Ablation Market – Company Profiles
1. Boston Scientific Corporation
2. Medtronic plc
3. Olympus Corporation
4. Stryker Corporation
5. Merit Medical Systems
6. HealthTronics, Inc.
7. Insightec
8. AngioDynamics
9. Integra LifeSciences
10. NeuWave Medical, Inc. (Johnson & Johnson MedTech)
11. EDAP TMS S.A.
12. Erbe Elektromedizin GmbH
13. IceCure Medical Ltd
14. Bioventus Inc. (Misonix Inc.)
15. Varian Medical Systems
For more details, please visit: https://apeloconsulting.com/reports/
Data Source
Apelo Consulting employs comprehensive primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by Apelo Consulting dedicated team of qualified professionals with deep industry experience and expertise.
